Skip to main content

Advertisement

Log in

Radiological predictive factors on preoperative multimodality imaging are related to Oncotype DX recurrence score in estrogen-positive/human epidermal growth factor receptor 2-negative invasive breast cancer: a cross-sectional study

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The Oncotype DX (ODX) estimates the 10-year risk of metastasis or recurrence of breast cancer and indicates whether chemotherapy is likely to be effective; however, the high cost of this test may limit its use for patients. The aim of this study was to evaluate the potential of preoperative imaging using mammography (MMG), ultrasonography (US), and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and positron emission tomography/computed tomography (PET/CT) metabolic parameters in predicting the ODX recurrence score (ODXRS), which prognosticates estrogen receptor-positive (ER +)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer.

Methods

This retrospective study was conducted on 51 patients with ER+/ HER2− early-stage breast cancer with preoperative images available. Surgical specimens were sent for ODX assay and the ODXRS was categorized as low (<18) or intermediate/high (≥18). MMG/US findings were classified according to BI-RADS categories. For MRI analysis, tumor growth orientation was evaluated in addition to morphological assessment in BI-RADS. For PET/CT analysis, standardized uptake value (SUV) of the tumor were measured. Patient, tumor, and image characteristics were compared between the two groups, and predictors of the low ODXRS group were determined by logistic regression analysis. Two-sided P values less than 0.05 were considered statistically significant.

Results

Thirty-two (63%) and 19 (37%) patients were categorized as low and intermediate/high ODXRS, respectively. On univariate analysis, nuclear grade, tumor margin, and tumor growth orientation on MRI, and SUVmax on PET/CT were significantly associated with a low ODXRS. Multivariate analysis revealed that tumor growth orientation perpendicular to the Cooper’s ligament on MRI (P = 0.031) and a low SUVmax on PET/CT (P = 0.016) were independent prognostic factors for a low ODXRS. As a predictor of low ODXRS, the receiver operating characteristic (ROC) analysis of the SUVmax showed that using 3.0 as the optimal cut-off value has a sensitivity and specificity of 94.4% and 73.0%, respectively, with an area under the curve (AUC) of 0.923.

Conclusions

The combination of perpendicular tumor growth orientation to Cooper’s ligaments on MRI and a low SUVmax on PET/CT may predict a low ODXRS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Boyages J, Taylor R, Chua B, Ung O, Bilous M, Salisbury E, et al. A risk index for early node-negative breast cancer. Br J Surg. 2006;93(5):564–71.

    Article  CAS  Google Scholar 

  2. Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia. 2001;6(4):375–92.

    Article  CAS  Google Scholar 

  3. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65.

    Article  CAS  Google Scholar 

  4. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015;373(21):2005–14.

    Article  CAS  Google Scholar 

  5. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26.

    Article  CAS  Google Scholar 

  6. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Net. 2009;7(2):122–92.

    Article  CAS  Google Scholar 

  7. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol. 2008;26(5):721–8.

    Article  Google Scholar 

  8. Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, et al. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg. 2008;196(4):527–9.

    Article  Google Scholar 

  9. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(10):1134–50.

    Article  CAS  Google Scholar 

  10. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 2011;22(8):1736–47.

  11. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999;17(1):110–9.

    Article  CAS  Google Scholar 

  12. Kim JY, Cho N, Koo HR, Yi A, Kim WH, Lee SH, et al. Unilateral breast cancer: screening of contralateral breast by using preoperative MR imaging reduces incidence of metachronous cancer. Radiology. 2013;267(1):57–66.

    Article  Google Scholar 

  13. Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, et al. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging. 2012;39(5):852–63.

    Article  CAS  Google Scholar 

  14. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20(8):1319–29.

    Article  CAS  Google Scholar 

  15. Tsukada H, Tsukada J, Schrading S, Strobel K, Okamoto T, Kuhl CK. Accuracy of multi-parametric breast MR imaging for predicting pathological complete response of operable breast cancer prior to neoadjuvant systemic therapy. Magn Reson Imaging. 2019;62:242–8.

    Article  Google Scholar 

  16. Oliveira TM, Brasileiro Sant’Anna TK, Mauad FM, Elias J Jr, Muglia VF. Breast imaging: is the sonographic descriptor of orientation valid for magnetic resonance imaging? J Magn Reson Imaging. 2012;36(6):1383–8.

    Article  Google Scholar 

  17. Landis JR, Koch GG. An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers. Biometrics. 1977;33(2):363–74.

    Article  CAS  Google Scholar 

  18. Saha A, Harowicz MR, Wang W, Mazurowski MA. A study of association of oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models. J Cancer Res Clin Oncol. 2018;144(5):799–807.

    Article  Google Scholar 

  19. Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, et al. MR Imaging radiomics signatures for predicting the risk of breast cancer recurrence as given by research versions of mammaprint, oncotype DX, and PAM50 Gene Assays. Radiology. 2016;281(2):382–91.

    Article  Google Scholar 

  20. Rawashdeh M, Lewis S, Zaitoun M, Brennan P. Breast lesion shape and margin evaluation: BI-RADS based metrics understate radiologists’ actual levels of agreement. Comput Biol Med. 2018;96:294–8.

    Article  Google Scholar 

  21. El Khoury M, Lalonde L, David J, Labelle M, Mesurolle B, Trop I. Breast imaging reporting and data system (BI-RADS) lexicon for breast MRI: interobserver variability in the description and assignment of BI-RADS category. Eur J Radiol. 2015;84(1):71–6.

    Article  Google Scholar 

  22. Elverici E, Zengin B, Nurdan Barca A, Didem Yilmaz P, Alimli A, Araz L. Interobserver and intraobserver agreement of sonographic BIRADS Lexicon in the assessment of breast masses. Iran J Radiol. 2013;10(3):122–7.

    Article  Google Scholar 

  23. Koo HR, Park JS, Kang KW, Han W, Park IA, Moon WK. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur Radiol. 2015;25(11):3314–21.

    Article  Google Scholar 

  24. Shimoda W, Hayashi M, Murakami K, Oyama T, Sunagawa M. The relationship between FDG uptake in PET scans and biological behavior in breast cancer. Breast Cancer. 2007;14(3):260–8.

    Article  Google Scholar 

  25. Lee SH, Ha S, An HJ, Lee JS, Han W, Im SA, et al. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer. Eur J Nucl Med Mol Imaging. 2016;43(9):1574–84.

    Article  CAS  Google Scholar 

  26. Cysouw MCF, Kramer GM, Schoonmade LJ, Boellaard R, de Vet HCW, Hoekstra OS. Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2017;44(12):2105–16.

    Article  Google Scholar 

  27. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21.

    Article  CAS  Google Scholar 

  28. Woodard GA, Ray KM, Joe BN, Price ER. Qualitative Radiogenomics: Association between Oncotype DX Test Recurrence Score and BI-RADS mammographic and breast MR imaging features. Radiology. 2018;286(1):60–70.

    Article  Google Scholar 

  29. Yepes MM, Romilly AP, Collado-Mesa F, Net JM, Kiszonas R, Arheart KL, et al. Can mammographic and sonographic imaging features predict the Oncotype DX recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? Breast Cancer Res Treat. 2014;148(1):117–23.

    Article  CAS  Google Scholar 

  30. Chae EY, Moon WK, Kim HH, Kim WH, Cha JH, Shin HJ, et al. Association between ultrasound features and the 21-Gene recurrence score assays in patients with oestrogen receptor-positive, HER2-negative, invasive breast cancer. PLoS ONE. 2016;11(6): e0158461.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing.

Funding

No funding was received for this study.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Jitsuro Tsukada or Tetsuya Ochi.

Ethics declarations

Conflict of interest

No potential conflicts of interest were disclosed.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsukada, H., Tsukada, J., Ochi, T. et al. Radiological predictive factors on preoperative multimodality imaging are related to Oncotype DX recurrence score in estrogen-positive/human epidermal growth factor receptor 2-negative invasive breast cancer: a cross-sectional study. Ann Nucl Med 36, 853–864 (2022). https://doi.org/10.1007/s12149-022-01767-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-022-01767-z

Keywords

Navigation